COLLABORATING MEDICAL CENTERS

Gorman Cardiovascular Research Group

UT Southwestern Radiology

Wafic Said Molecular Cardiology Lab

Austin Heart Hospital

UT Dell Medical School
COLLABORATING ENGINEERING LABORATORIES

Cardiovascular Fluid Mechanics Laboratory

Artificial Heart & Cardiovascular Fluid Dynamics Lab

Computational Fluid-Structure Interaction Laboratory

LATEST NEWS:
CCS Renamed in Honor of Distinguished Alumnus Dr. James Willerson
The University of Texas at Austin has named a top cardiovascular research center at the Institute for Computational Engineering and Sciences (ICES) in honor of internationally acclaimed cardiologist Dr. James Willerson. Willerson is a distinguished UT Austin alumnus, president emeritus of the Texas Heart Institute and former president of The University of Texas Health Science Center at Houston.

Read more about the distinguished renaming here.


MISSION STATEMENT:
The overarching goal of the Willerson Center for Cardiovascular Modeling and Simulation (WCCMS) is developing computational biomechanical models for understanding heart valve and heart disease progression for developing clinical interventions, including prosthetics devices. We develop or utilize a range of unique in-vivo and in-vitro data for elucidating mechanisms that underlie the observed pathologies.  Our modeling focus is the detailed incorporation of this data to provide a high level of physical and physiological realism and validation, working at the continuum-cellular, fibrous tissue, and whole organ levels. We ultimately seek to provide cardiovascular scientists and clinicians with advanced simulations for the rational development of treatments for structural heart and heart valve diseases. Such simulations can ultimately lead to reduction in development time, lowering of morbidity and mortality, reduced re-operative rates, and lessened post-operative recovery time. Moreover, the development and use of these tools in the context of patient-specific models will ultimately also allow clinicians to craft cardiovascular therapies that are optimized for the cardiovascular system of individuals, with a resulting increase in success and decrease in risk adverse side effects.

Michael Sacks, Director


2017 WCCMS Group Photo

Downloadable Brochure (PDF)